Klin Farmakol Farm. 2005;19(3):186-187

Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children

Zdeněk Doležel, Jiří Štarha, Dana Dostálková
II. dětská klinika LF MU a FN Brno

Our clinical trial evaluated the pharmacokinetics of mycophenolate mofetil in children with autoimmune diseases. Base on the pharmacokinetics data obtained paediatric dose recommendations for patient with vasculitis/connective tissue disease were derived.

Keywords: Key words: autoimmune diseases, mycophenolate mofetil, dosage, childhood.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležel Z, Štarha J, Dostálková D. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Klin Farmakol Farm. 2005;19(3):186-187.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Burratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mocyphenolate mofetil treatment of severe renal diseases in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-2108. Go to PubMed...
    2. Filler G, Ehrich JHH. Mycophenolic mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration. Nephrol Dial Transplant 1997; 12: 374-375. Go to original source... Go to PubMed...
    3. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppresion. Pediatr Nephrol 2000; 14: 100-104. Go to original source... Go to PubMed...
    4. Filler G, Hansen M, LeBlanc C, Lepage N, Franke D et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003; 18: 445-449. Go to original source... Go to PubMed...
    5. Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606-611. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.